Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Gains from Investment Securities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Gains from Investment Securities for 4 consecutive years, with $300000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 21.95% to $300000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2025, up 21.95% year-over-year, with the annual reading at $12531.0 for FY2025, 72.83% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $300000.0 at Spruce Biosciences, up from $246000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $1.4 million in Q4 2022, with the low at -$83000.0 in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $368224.7, with a median of $246000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities crashed 106.02% in 2023, then soared 396.39% in 2024.
  • Over 4 years, Gains from Investment Securities stood at $1.4 million in 2022, then plummeted by 106.02% to -$83000.0 in 2023, then skyrocketed by 396.39% to $246000.0 in 2024, then grew by 21.95% to $300000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $300000.0, $246000.0, and -$83000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.